Immunic Stock Gets Reduced EPS Estimate from HC Wainwright

Immunic, Inc. (NASDAQ:IMUX – Free Report) – Stock analysts at HC Wainwright cut their FY2030 earnings per share (EPS) estimates for shares of Immunic in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings per share of $0.33 for the year, down from their prior estimate of $0.40. HC Wainwright has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Immunic’s current full-year earnings is ($3.69) per share.

Several other analysts have also issued reports on IMUX. Ladenburg Thalmann & Co. Inc. upgraded Immunic to a “strong-buy” rating in a report on Wednesday, July 29th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Immunic in a report on Thursday, September 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Zacks Research lowered shares of Immunic from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 10th. Finally, Roth Capital reiterated a “buy” rating on shares of Immunic in a report on Tuesday, September 1st. Three investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.43.

Get Our Latest Research Report on Immunic

Immunic Stock Down 3.9%

Shares of IMUX opened at $7.23 on Tuesday. The company’s 50 day moving average price is $8.58 and its 200 day moving average price is $11.53. Immunic has a 52 week low of $5.06 and a 52 week high of $17.43.

Immunic (NASDAQ:IMUX – Get Free Report) last issued its earnings results on Friday, November 13th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20).

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP raised its stake in shares of Immunic by 242.8% in the 3rd quarter. Marshall Wace LLP now owns 359,319 shares of the company’s stock valued at $3,342,000 after buying an additional 254,503 shares in the last quarter. State Street Corp boosted its position in shares of Immunic by 36.9% during the 3rd quarter. State Street Corp now owns 83,859 shares of the company’s stock valued at $780,000 after acquiring an additional 22,600 shares in the last quarter. Aberdeen Group plc boosted its position in shares of Immunic by 32.3% during the 3rd quarter. Aberdeen Group plc now owns 1,090,427 shares of the company’s stock valued at $10,141,000 after acquiring an additional 266,034 shares in the last quarter. Alps Advisors Inc. increased its stake in Immunic by 28.0% in the third quarter. Alps Advisors Inc. now owns 17,694 shares of the company’s stock valued at $165,000 after acquiring an additional 3,870 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in Immunic by 21.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,800 shares of the company’s stock valued at $69,000 after acquiring an additional 1,400 shares during the period. Institutional investors own 51.82% of the company’s stock.

About Immunic

(Get Free Report)

Immunic, Inc. is a clinical-stage biopharmaceutical company developing oral small-molecule treatments for chronic inflammatory and autoimmune diseases. The company’s research focuses on therapies intended to address conditions with significant unmet medical needs. Its lead drug candidate, vidofludimus calcium, is being developed for multiple sclerosis. Immunic is also advancing other investigational compounds, including IMU-856, which is being studied for its potential to support intestinal barrier function in gastrointestinal diseases.

Further Reading

Earnings History and Estimates for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.